Home 2016-10-24T12:33:21+00:00

RadioMedix and Orano Med receive FDA Orphan Drug Designation for AlphaMedix(TM) for the treatment of neuroendocrine tumors

RadioMedix and ITM announce agreement for manufacturing of Ge-68/Ga-68 generators in U.S
clinicaltrial

RadioMedix and AREVA Med announce initiation of Phase 1 clinical trial of AlphaMedixTM, a Targeted Alpha Therapy for patients with neuroendocrine tumors

RadioMedix Selected for National Cancer Institute’s Investor Initiatives and Presentation at BIO Investor Forum

ITG productsSlide thumbnail

Extended partnership between Radiomedix INC and ITM´s subsidiary ITG for exclusive distribution of n.c.a Lutetium-177 in North America

RadioMedix and ITM announce agreement for manufacturing of Ge-68/Ga-68 generators in U.S.
[image]
RadioMedix Selected for National Cancer Institute’s Investor Initiatives and Presentation at BIO Investor Forum
Slide thumbnail
Extended partnership between Radiomedix Inc and ITM´s subsidiary ITG for exclusive distribution of n.c.a Lutetium-177 in North America
RadioMedix Inc. and AREVA Med Announce Completion of the Exploratory Clinical Trial of 203Pb-AR-RMX in patients expressing somatostatin receptor positive neuroendocrine tumors
Slide thumbnail
RadioMedix, Inc., received an exclusive distributions rights for SEDECAL Preclinical PET-CT and PET-MR systems in North America.
Slide thumbnail
The Phase II Clinical Trial of 177 Lu PSMA-617 Targeted Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer Receives FDA Clearance
RadioMedix and AREVA Med - SBIR NCI Contract awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212.
RadioMedix Inc. successfully completed the Phase I/ II clinical studies for AminoMedix ™ used for radiation kidney protection during Peptide-Receptor Radionuclide Therapy (PRRT)
Slide thumbnail
RadioMedix secured a second SBIR NCI grant for image guided therapy for metastatic melanoma
RadioMedix Successful Installations of SmartMedixTM  and AIO fully automated synthesizer modules in USA.
RadioMedix Inc. launches SmartMedix™ synthesizers powered by Trasis in USA
RadioMedix initiates the first Ga-68 PSMA (ProstaMedix™) clinical trial for diagnosis and management of prostate cancer in U.S.
RadioMedix Inc. granted exclusive distribution authorization for ITG 68Ge/68Ga generators, and ITG iQS® Ga-68 Fluidic Labelling Module in U.S.A.

Innovating Theranostics

RadioMedix, Inc. is a biotechnology company, based in Houston, Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring and therapy of cancer. The company is commercializing generator-produced radiopharmaceuticals based on Gallium-68 chemistry. RadioMedix is in late-stage development of a new radiolabeled analog targeting metabolic pathway, GlucoMedix, which is based on its patented DO2A-chelation technology.

RadioMedix is introducing the SmartMedix™ automated laboratory system for synthesis of PET tracers for the research and clinical markets. RadioMedix has also established two service facilities for academic and industrial partners: cGMP Manufacturing Suite for clinical probe development and Molecular Imaging Facility for evaluation of agents in animal models.

Recent News


RadioMedix and Orano Med receive FDA Orphan Drug Designation for AlphaMedix(TM) for the treatment of neuroendocrine tumors

November 13th, 2018|Comments Off on RadioMedix and Orano Med receive FDA Orphan Drug Designation for AlphaMedix(TM) for the treatment of neuroendocrine tumors

RadioMedix and ITM announce agreement for manufacturing of Ge-68/Ga-68 generators in U.S.

July 25th, 2018|Comments Off on RadioMedix and ITM announce agreement for manufacturing of Ge-68/Ga-68 generators in U.S.

RadioMedix and AREVA Med announce initiation of Phase 1 clinical trial of AlphaMedixTM, a Targeted Alpha Therapy for patients with neuroendocrine tumors

January 10th, 2018|Comments Off on RadioMedix and AREVA Med announce initiation of Phase 1 clinical trial of AlphaMedixTM, a Targeted Alpha Therapy for patients with neuroendocrine tumors

RadioMedix Selected for National Cancer Institute’s Investor Initiatives and Presentation at BIO Investor Forum

October 23rd, 2017|Comments Off on RadioMedix Selected for National Cancer Institute’s Investor Initiatives and Presentation at BIO Investor Forum

Extended partnership between Radiomedix Inc and ITM´s subsidiary ITG for exclusive distribution of n.c.a Lutetium-177 in North America

October 10th, 2017|Comments Off on Extended partnership between Radiomedix Inc and ITM´s subsidiary ITG for exclusive distribution of n.c.a Lutetium-177 in North America

RadioMedix Inc. and AREVA Med Announce Completion of the Exploratory Clinical Trial of 203Pb-AR-RMX in patients expressing somatostatin receptor positive neuroendocrine tumors

June 21st, 2017|Comments Off on RadioMedix Inc. and AREVA Med Announce Completion of the Exploratory Clinical Trial of 203Pb-AR-RMX in patients expressing somatostatin receptor positive neuroendocrine tumors